嵌合抗原受体修饰T细胞免疫治疗肿瘤的研究进展  

Advances in Cancer Immunotherapy Adopting Chimeric Antigen Receptor-modified T Lymphocytes

作　　者：欧剑锋[1] 王蕾[1] 潘耀柱[1] 张姝婷[1] 白海[1] 

机构地区：[1]兰州军区兰州总医院血液科,甘肃兰州730050

出　　处：《现代生物医学进展》2016年第2期373-376,319,共5页Progress in Modern Biomedicine

基　　金：国家自然科学基金项目(81372132)

摘　　要：以嵌合抗原受体修饰T细胞(chimeric antigen receptor modified-T lymphocytes,CAR-T)为基础的过继细胞免疫治疗近年来成为治疗恶性肿瘤的一种新模式。CAR-T细胞赋予T细胞靶向杀伤活性,并可克服肿瘤免疫抑制和打破宿主免疫耐受。尽管目前CAR-T的临床应用还存在诸如脱靶效应、细胞因子风暴、插入突变和移植物抗宿主病样损伤等许多问题,但我们相信随着对CAR-T细胞的深入研究及推广应用将会大幅度提高肿瘤的临床治疗效果。本文就CAR-T细胞应用于肿瘤免疫治疗的前生、今世和将来作一综述。Chimeric antigen receptor modified-T lymphocytes（CAR-T） based adoptive antitumor immunotherapy has became an emerging therapeutic modality for malignant tumor in recent years. CAR-T cells give the targeted killing activity of T lymphocytes,which they can resist the tumor immunosuppression and break the host immune tolerance. Although there still exist many problems for CAR-T on the clinical application such as off-target effects, cytokine storm, insertion mutagenesis, graft versus host disease-like damage and many other problems, but we believe that with the in-depth study of the CAR-T cells and application will greatly improve the therapeutic effects of tumor. We summarized the past history, present status and future prospect of tumor immunotherapy adopting CAR-T in this review.

关 键 词：嵌合抗原受体 T细胞 免疫治疗 肿瘤 

分 类 号：R730[医药卫生—肿瘤] R733[医药卫生—临床医学]